On Wednesday, Jefferies analyst Glen Santangelo revised the price target for Phathom Pharmaceuticals (NASDAQ:PHAT) shares, reducing it to $13 from the previous $17, while continuing to recommend the stock as a Buy.
On Wednesday, Jefferies analyst Glen Santangelo revised the price target for Phathom Pharmaceuticals (NASDAQ:PHAT) shares, reducing it to $13 from the previous $17, while continuing to recommend the stock as a Buy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.